Hearscape
← Therapeutics
Details checkedStatus confirmedHistorical/discontinuedCheckedcompany

OTO-313 by Otonomy

Also known as: OTO-313, gacyclidine formulation

Otonomy

Primary source
Company
Otonomy
Program Type
Therapeutic
Modality
Small Molecule
Stage
Phase 2
Status
Discontinued
Target Gene
—
Route / Mode
Intratympanic injection
Confidence
96%
Status Confidence
Status confirmed
Evidence Strength
Needs more support
Last Reviewed
2026-05-31
Geography
United States
Population
adult, tinnitus, unilateral
Trial IDs
2
Mechanism

Sustained-exposure intratympanic NMDA receptor antagonist formulation intended to reduce acute inner-ear tinnitus.

Indications
Tinnitus
Notes

One of the most visible tinnitus drug programs of the last cycle; discontinued after Phase 2 failure and before Otonomy's liquidation.

Evidence & Sources
3 structured sources
company
Supports: canonicalName, aliases, stage, status, indications, notes
IDs: OTO-313
Open
company
Supports: mechanism, route, populationTags
IDs: OTO-313
Open
company
Supports: company, allCompanies
IDs: Otonomy
Open
Key Events
2022-08-01
Otonomy discontinued OTO-313 after a negative Phase 2 tinnitus readout
Clinical Trials (2)
NCT04829214NCT03918109
Related Programs
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
AC102 by AudioCure Pharma
Company: AudioCure Pharma · Small Molecule · Phase 2
SPI-1005 by Sound Pharmaceuticals
Company: Sound Pharmaceuticals · Small Molecule · Phase 3
ACOU085 by Acousia Therapeutics
Company: Acousia Therapeutics GmbH · Small Molecule · Phase 2
CIL001 (Paliroden) by Cilcare
Company: Cilcare SAS · Small Molecule · Phase 1/2